Novel lentiviral model can determine effect of Wnt/β-Catenin inhibition on bone regeneration

Researchers have developed a novel tool for determining the sensitivity of bone healing to inhibition of the Wnt signaling pathway and have validated its use in a study of bone regeneration in mice. The tool, which is based on a lentivirus encoding a β-catenin shRNA model, is described in an article published in Tissue Engineering, Part A, peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Aaron James, MD, PhD, Johns Hopkins University (JHU, Baltimore, MD) and coauthors from JHU, China Medical University (Shenyang), University of California San Diego, School of Medicine, University of California Los Angeles, UCLA School of Dentistry, and UCLA David Geffen School of Medicine report their findings in the article entitled "Frontal Bone Healing Is Sensitive to Wnt Signaling Inhibition Via Lentiviral Encoded Beta-Catenin Short Hairpin RNA." Their lentiviral model allows for specific and localized inhibition of the Wnt/β-Catenin signaling pathway, which plays a critical role in skeletal biology. Researchers can use the model to determine the effect of Wnt/β-Catenin inhibition on bone maintenance and regeneration during bone repair.

"The continued development of gene therapy approaches is critical to the success of the regenerative medicine field. The work presented here by Dr. James and his collaborators demonstrates a critical success in this field and its particularly important application in bone tissue engineering," says Tissue Engineering Co-Editor-in-ChiefJohn P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, College Park.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New type of immunotherapy shows promising preclinical results against osteosarcoma